SARS-CoV-2 刺突治疗性抗体在变异体时代。
SARS-CoV-2 spike therapeutic antibodies in the age of variants.
机构信息
Regeneron Pharmaceuticals Inc., Tarrytown, NY.
出版信息
J Exp Med. 2021 May 3;218(5). doi: 10.1084/jem.20210198.
Abstract
Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2.
摘要
再生元制药公司（Regeneron Pharmaceuticals）研究副总裁、传染病和病毒载体技术专家 Christos Kyratsous 与再生元制药公司传染病副总监 Alina Baum 探讨了针对 SARS-CoV-2 刺突蛋白的抗体疗法的研发。
相似文献
1
SARS-CoV-2 spike therapeutic antibodies in the age of variants.
J Exp Med. 2021 May 3;218(5). doi: 10.1084/jem.20210198.
2
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
3
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
4
SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test.
Eur J Clin Invest. 2021 Jul;51(7):e13573. doi: 10.1111/eci.13573. Epub 2021 May 5.
5
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.
Front Immunol. 2021 Nov 15;12:761250. doi: 10.3389/fimmu.2021.761250. eCollection 2021.
6
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
7
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
mBio. 2021 Jun 29;12(3):e0069621. doi: 10.1128/mBio.00696-21. Epub 2021 Jun 1.
8
Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.
J Infect Dis. 2022 Mar 15;225(6):938-946. doi: 10.1093/infdis/jiab540.
9
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
10
A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding.
Biochem Biophys Res Commun. 2021 Sep 24;571:152-158. doi: 10.1016/j.bbrc.2021.07.062. Epub 2021 Jul 20.
引用本文的文献
1
Bispecific antibodies targeting MPXV A29 and B6 demonstrate efficacy against MPXV infection.
J Virol. 2025 May 20;99(5):e0232024. doi: 10.1128/jvi.02320-24. Epub 2025 Apr 3.
2
On the collection and integration of SARS-CoV-2 genome data.
Biosaf Health. 2023 Jul 4;5(4):204-210. doi: 10.1016/j.bsheal.2023.07.004. eCollection 2023 Aug.
3
Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant.
J Microbiol Biotechnol. 2023 Dec 28;33(12):1587-1295. doi: 10.4014/jmb.2308.08020. Epub 2023 Nov 3.
4
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial.
Open Forum Infect Dis. 2023 Apr 19;10(5):ofad211. doi: 10.1093/ofid/ofad211. eCollection 2023 May.
5
Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth.
Nat Commun. 2022 Sep 22;13(1):5552. doi: 10.1038/s41467-022-33284-y.
6
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
Int J Infect Dis. 2022 Sep;122:585-592. doi: 10.1016/j.ijid.2022.06.045. Epub 2022 Jul 2.
7
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.
BioDrugs. 2022 May;36(3):231-323. doi: 10.1007/s40259-022-00529-7. Epub 2022 Apr 27.
8
Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth.
bioRxiv. 2022 Feb 1:2022.02.01.478504. doi: 10.1101/2022.02.01.478504.
9
Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications.
Curr Microbiol. 2021 Dec 14;79(1):20. doi: 10.1007/s00284-021-02724-1.
10
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days.
Contemp Clin Trials. 2022 Feb;113:106652. doi: 10.1016/j.cct.2021.106652. Epub 2021 Dec 9.
本文引用的文献
1
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. Reply.
N Engl J Med. 2021 Nov 11;385(20):e70. doi: 10.1056/NEJMc2113862. Epub 2021 Oct 6.
2
ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply.
N Engl J Med. 2021 Aug 5;385(6):571-572. doi: 10.1056/NEJMc2110093. Epub 2021 Jul 21.
Zotero 插件